Mener vel at de har snakket så lenge om dette, og har hatt analyse av de beste sykehusene som skal være med at de burde bestemt allerede om noen skal være med. Slik jeg ser det er det bare en grunn til at de ikke har gjort det. Hvorfor har de ikke bestemt seg når regionen er så viktig?
Det er også verdt å merke seg spørsmålet om når det er aktuelt å få en partner, Sier han at på Asia er det aktuelt med en partner tidligere enn det er for vesten.
Coming back to the hospitals – possible hospitals in Asia. When do you think you will know there’s going to be included any hospital in Asia in the pivotal II study?
Per Walday, PCI Biotech Holding ASA - CEO [44]
First half of next year, I would think, we would have a clear picture of that.
I mean, the most likely scenario is that you take this – we now have the funding to bring this all the way to interim analysis and a potential successful approval. Then the most likely scenario is to wait to – until you actually have those results available. Now there are other areas in the world as well that we are not discussing. We have been discussing with EMA and the FDA. As I mentioned, Asia is a big territory and there are possibilities of looking into how to attract interest from that area and that might be done at an earlier stage than we do for the Western world. But these are strategic considerations and open discussions that we have.
[Tron Johannsen]. Regarding Asia, will you have Asian sites also into the study? You had an open possibility for that a little bit earlier?
Per Walday, PCI Biotech Holding ASA - CEO [14]
Yes, we still have an open possibility for that. But we’re considering how to do this the best possible way, so we’ll get back to that when we have concluded those deliberations. But it is important – it is an important region so somehow we need to define a strategy for how we handle that region.
